02.08.2021 • NewsHaldor Topsøe

Haldor Topsoe in China Methanol Catalysts Venture

Haldor Topsoe has formed a joint venture with Shaanxi Yanchang Petroleum to build a plant in Shaanxi Fupin in China to produce methanol synthesis catalysts for the Chinese market.

The companies have already designed the plant and ordered long lead time equipment and plan to start production at the beginning of 2022.

“Yanchang is well-positioned in the oil and gas value chain and a very experienced methanol producer. With this joint venture we combine Topsoe’s world-leading methanol catalyst technology and Yanchang’s outstanding production capabilities to produce our high-performance methanol synthesis catalysts that Topsoe will sell directly to our Chinese customers, enhancing our presence in the Chinese market,” says Amy Hebert, Topsoe’s chief commercial officer.

Topsoe said the formation of the jv and the building of the catalysts facility will be the first step of a long-term strategic cooperation between the companies.

Author: Elaine Burridge, Freelance Journalist

Haldor Topsoe has formed a joint venture with Shaanxi Yanchang Petroleum to...
Haldor Topsoe has formed a joint venture with Shaanxi Yanchang Petroleum to build a plant in Shaanxi Fupin, China, to produce methanol synthesis catalysts. The companies have designed the plant and ordered long lead time equipment with start-up due at the beginning of 2022. (c) Haldor Topsoe

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.